Although the average daily dose of the oral anticoagulant warfarin is 5 mg, there is wide interpatient variability in the dosage requirements (1). Dietary intake of vitamin K, concurrent medications, hepatic impairment, albumin levels, age, and adherence to therapy can profoundly influence dosage requirements. A growing body of evidence is pointing to genetic polymorphism of the major cytochrome P450 (CYP) isoenzyme responsible for warfarin metabolism as an additional explanation for this variability.
been shown that CYP2C9 exhibits genetic polymorphism, rendering carriers of some variant alleles less effective at metabolizing substrate medications. Most CYP2C9 variants arise from amino acid substitutions in the coding region of the CYP2C9 gene (5, 6) . The metabolic activity of the variant alleles is often expressed as a percentage of the activity of CYP2C9*1, the wild-type allele. CYP2C9*2 and CYP2C9*3 were the first variant alleles documented (5, 7) and are the most commonly reported. Catalytic activity of the CYP2C9*3 protein is approximately 5% of that associated with the wild type CYP2C9*1 protein toward S-warfarin (8, 9) . Enzyme activity of CYP2C9*2 homozygotes has been found to be either between 80% and 84% of CYP2C9*1 homozygotes (10) or unchanged (11, 12) . Other variants identified more recently have been named CYP2C9*4 through CYP2C9*12 (13, 16 ). An enzyme kinetic study revealed that the metabolic capacity of the CYP2C9*5 variant is 8% of that observed in CYP2C9*1 (14) . CYP2C9*6 is a null mutation that is devoid of activity (15) . We report 2 cases of CYP2C9 genetic polymorphisms and elevated warfarin S:R ratios in patients taking low doses of warfarin and compare these to published reports.
Case 1
A 37-year-old white male nonsmoker, who had been stabilized on a weekly warfarin dose of 10.5 mg was evaluated for warfarin S:R ratio and CYP2C9 genotype. His indications for warfarin therapy included recurrent venous thromboembolic events and lupus. At the time of blood sampling, the patient had no other medical problems, was taking no medications besides warfarin, had normal liver function, and had albumin levels within the normal range.
The patient initiated long-term therapy with warfarin in 1994. Records available from 1997 and 1998 reveal that the patient had been maintained on a warfarin dose within the narrow range of 9 to 10 mg per week. While on these low weekly warfarin doses, International Normalized Ratio (INR) results of 4.60 and 3.72 were attributed to idiosyncratic reactions to foods such as cantaloupe, cabbage, spinach, and oranges.
In 1999, he transferred his care to the current institution and was self-described as "warfarin sensitive." He was referred to the institution's Anticoagulation Clinic in May 2000 following a deep vein thrombosis (DVT) of the left leg. At the time of enrollment, the patient was taking a weekly warfarin dose of 9 mg. In September 2000, his goal INR range was increased from 2.0 to 3.0 to a range of 2.5 to 3.5. To better reach this goal, his weekly warfarin dose was increased from 10 to 15.5 mg per week. The INR subsequently reached as high as 8.48 and the patient developed hematuria and epistaxis. In addition, within the same interval, a minor traumatic incident resulted in a persistent elbow hematoma. The patient was closely monitored during this time.
Throughout the following 2 months, the patient visited the clinic 7 times and his warfarin dosage was titrated downward. In November 2000, his optimal warfarin dose was determined to be 10.5 mg per week ( Fig. 1 ). He has had consistently therapeutic INR results with no bleeding episodes for 27 months on this dose.
Clinic providers had been perplexed by the very low warfarin dosage requirements in this otherwise healthy patient. It was suspected that the cause might be aberrant warfarin metabolism. In 2000, a sample of blood was collected from this patient and sent for S-and R-warfarin concentration analysis and CYP2C9 genotyping. At the time of sample collection, the patient's INR was 3.05. The results confirmed the suspicion that impaired warfarin metabolism was contributory. Warfarin S and R concentrations assessed using a previously published technique (3) revealed that the patient's warfarin S:R ratio was 1:1. This is double the expected ratio of 0.5:1, evidence that the patient had impaired clearance of S-warfarin. Moreover, this reduction in the clearance of S-warfarin could be explained by impaired CYP2C9 activity. Genetic analysis of the *2 locus by restriction fragment length polymorphism (RFLP) and of the *3 and *5 loci by direct sequencing of exon 7 (9) revealed that the patient was CYP2C9*3/*1 heterozygous.
Several studies have evaluated the influence of CYP2C9 genetic polymorphisms on warfarin dose, plasma concentrations, clearance, and anticoagulant response (7, (17) (18) (19) (20) . Takahashi and colleagues (7) reported that the weekly warfarin dose and unbound oral clearance of warfarin in CYP2C9*3 heterozygotes was 33% less than that in CYP2C9*1 homozygotes. Aithal and colleagues (18) found that patients taking low doses of warfarin (< 10.5 mg/week) were more likely to be either heterozygous or homozygous for either CYP2C9*2 (odds ratio [OR] 2.68; 95% confidence interval [CI] 1.22-5.86) or CYP2C9*3 (OR 7.8; 95% CI 1.90-32.1). They found that patients taking low warfarin doses were at increased risk of having an elevated INR when starting therapy (OR 5.97; 95% CI 2. 25-15.82 ) and were at increased risk of having a serious or life-threatening bleeding episode (OR 3.68; 95% CI 1.43-9.50). Higashi and colleagues (19) reported that patients with a variant CYP2C9 allele have an increased risk of serious or life-threatening bleeding events (hazard ratio [HR] 2.39; 95% CI, 1.18-4.86), an increased risk of elevated INRs (HR 1.40; 95% CI 1.03-1.90), and require more time to achieve stable dosing (HR 0.65; 95% CI 0.45-0.94). Scordo and colleagues (20) found that the frequency of variant CYP2C9 alleles was significantly higher (p<0.001) in patients receiving low warfarin doses (< 26.25 mg/week) compared to those receiving medium doses (26.25-43.75 mg/week). They found that the unbound oral clearance of S-warfarin for CYP2C9*3 and CYP2C9*2 homozygotes was 10% and 33%, respectively, of the unbound oral clearance noted for CYP2C9*1 homozygotes. They suggest that the mean unbound oral clearance corresponds to the following order: *3/*3 < *3/*2 < *2/*2 < *3/*1 < *2/*1 < *1/*1 and propose that the warfarin S:R ratio would follow the reverse sequence.
Case 2
A 77-year-old African American male smoker, who had been stabilized on a weekly warfarin dose of 10 mg was evaluated for warfarin S:R ratio and CYP2C9 genotype. He was being treated with warfarin for recurrent VTE and cerebrovascular accident. At the time of blood sampling, the patient's medical history was significant for hypertension, coronary artery disease, benign prostatic hypertrophy, osteoarthritis, anemia, and diverticulosis. The only medication he was taking besides warfarin was terazosin which does not interact significantly with warfarin (21, 22) . The patient had normal liver function and had albumin levels within the normal range.
The patient had been followed by the institution's Anticoagulation Clinic since starting warfarin therapy in 1992. He presented to his initial appointment in August 1992 with an INR of 12.37 after receiving warfarin doses between 7.5 and 20 mg per day while admitted and 5 mg per day upon discharge. Even once the weekly warfarin dose was decreased to 17.5 mg, the INR remained elevated at 10.79. Subsequent dosage adjustments revealed that a weekly warfarin dose within the narrow range of 9 to 10 mg was optimal for this patient. Although there have been some variations in the exact dosage regimens, the patient has been stable on a weekly warfarin dose between 9 and 10 mg from 1992 to the present.
This patient's consistently low warfarin requirements were another clinic mystery. Again, how does one explain such consistently low dosage requirements when drug interactions and decreased organ function have been ruled out? In 2001, a sample of blood was collected from this patient and sent for S-and R-warfarin concentration analysis and CYP2C9 genotyping. The patient's INR was 2.42 at this time. Using previously published methods (3), it was discovered that the patient's warfarin S:R ratio was 3.2:1. This is over 6 times the expected ratio of 0.5:1, and provides clear evidence of impaired S-warfarin clearance. With this high degree of impairment in S-warfarin metabolism, this patient would certainly be expected to have at least 1, or perhaps even 2, variant CYP2C9 alleles. However, genetic analysis of the *2 locus by restriction fragment length polymorphism (RFLP) and of the *3 and *5 loci by previously published methods (9) revealed neither CYP2C9*2 nor CYP2C9*3. In 2002, the blood was sent to another source where CYP2C9*6 genotyping was performed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) (15) . As suspected, the patient did carry variant CYP2C9 alleles. He was found to be homozygous for the null CYP2C9*6 allele.
With 1 exception to date (19) , clinic-based studies evaluating CYP2C9 genetic polymorphisms and warfarin parameters have only reported results in terms of the CYP2C9*1, CYP2C9*2, and CYP2C9*3 genotypes (14) . CYP2C9*6, recently identified and characterized by Kidd and colleagues, was found in a patient exhibiting severe phenytoin toxicity (15) . It has been described as a null mutation with a base deletion A818 leading to a frameshift, early stop codon, and truncated protein devoid of any CYP2C9 activity. The frequency of this allele was found to be 0.6% among an African-American population studied while it was not identified among the population of French whites studied.
DISCUSSION
The patient in the first case, a relatively young white male, was heterozygous for CYP2C9*3 and had a warfarin S:R ratio double that of the expected ratio of 0.5:1. He had been stabilized on a weekly warfarin dose of 10.5 mg, 30% of the average weekly dose of 35 mg. His profile is consistent with previous reports of patients requiring low warfarin doses, ranging from less than 10.5 mg to less than 26.25 mg/week, having at least one variant CYP2C9 allele (7, 18, 20) . Because some of his medical records are not available, it is not known how long it took to determine this patient's optimal warfarin dose. If he had been started on the average dose of 5 mg per day, it may have taken several months of gradual dosage reductions. During this period, the patient's risk for bleeding would have remained elevated. The patient's self-description of being "warfarin sensitive" suggests that he may have had exaggerated responses in his INR. His medical records even describe some elevated INRs as being idiosyncratic reactions. Knowing his CYP2C9 genotype now provides a plausible explanation for these responses.
Shortly after assuming care at the current institution, the patient's warfarin dose was increased to 14 mg per week. The response was an INR reaching a high of 8.46 and the development of hematuria, nosebleed, and persistent elbow hematoma. This necessitated more frequent clinic visits to monitor the INR, check for the resolution of bleeding symptoms, and adjust the dose of warfarin. The patient's 7 Anticoagulation Clinic appointments over a 2-month period were certainly in excess of the monthly follow-up intervals recommended (1, (23) (24) (25) . In retrospect, if this patient's impaired ability to metabolize Swarfarin had been known, a much more conservative approach to dosage adjustment could have been taken.
The patient in the second case, an elderly African-American male, was homozygous for CYP2C9*6 and had a warfarin S:R ratio over 6 times the expected ratio of 0.5:1. As opposed to the first case, he had neither the CYP2C9*2 nor CYP2C9*3 variant alleles that had been evaluated in studies of patients taking low warfarin doses (7, 18, 20) . This is, in fact, the first published report of homozygous CYP2C9*6 in a patient taking warfarin.
Consistent with the first case presented, this patient's warfarin dose was approximately 30% of the average warfarin dose of 35 mg/week. This patient had been started on the average dose resulting in a markedly elevated INR. As discussed previously, during the period of determining his optimal warfarin dose, his risk for bleeding would have remained elevated. If this patient's impaired functioning of the CYP2C9 enzyme had been known at the time of therapy initiation, he could have been started on a much lower dose of warfarin.
There are several consistencies between this CYP2C9*6 homozygote taking warfarin and the population in which CYP2C9*6 was first studied (15) . There is a racial parallel in that CYP2C9*6 has only been found in African Americans to date as is the patient at hand. The patient in which CYP2C9*6 was first identified had been taking phenytoin, another CYP2C9 enzyme substrate with a narrow therapeutic index. After taking phenytoin 100 mg 3 times daily for 13 days, she presented with slurred speech, mental confusion, memory loss, and the inability to stand. Her phenytoin level was 49.5 µg/mL, indicating severely impaired CYP2C9 enzyme function (15) . The patient in the present case had a warfarin S:R ratio more than 6 times higher than expected, also indicating severely impaired warfarin metabolism. However, he did not manifest symptoms of warfarin toxicity and had an INR within the therapeutic range at the time of blood collection. Although he had had markedly elevated INRs during initiation of therapy, there is no documentation of bleeding episodes. Perhaps his status as a smoker helped avert such episodes through a compensatory increase in CYP1A2 activity with a resultant increase in R-warfarin metabolism.
CONCLUSION
Although warfarin is commonly initiated at a dose of 5 mg per day (1), clinicians should be aware that some patients will require much lower doses due to the genetic polymorphisms described. While adjusting the dose downward in these patients, the risk remains for bleeding episodes and elevated INRs. If patients could be genotyped for CYP2C9 before starting warfarin and other CYP2C9 substrates, the delays in determining the optimal dose could be averted and the potential for adverse effects could be decreased.
